Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib plus ibrutinib versus ibrutinib alone in Waldenström's macroglobulinemia
2018-003526-88Phase 2Active
- Sponsor
- University Hospital Ulm
- Start
- Aug 2020
- Modality
- Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of carfilzomib and ibrutinib in Waldenström macroglobulinemia (WM) (2 arms), sponsored by University Hospital Ulm. Primary endpoint: CR or VGPR rate at 12 months. Started Aug 2020; status: active.
02
Drugs
carfilzomibibrutinib
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on 2018-003526-88.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003526-88.